| Prev Close | 621.40 |
| Open | 613.13 |
| Day Low/High | 601.25 / 623.54 |
| 52 Wk Low/High | 441.00 / 686.62 |
| Volume | 1.12M |
Regeneron Pharmaceuticals, Inc. (REGN)
621.48
0.08
0.01
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 107.57B |
| Market Cap | 66.09B |
| P/E Ratio | 19.71 |
| Div & Yield | N.A. (N.A) |
Latest News
Should Investors Believe in Bounces as Markets Get Choppy?
Sector selection will remain paramount as pandemic effects continue to permeate.
Faux Rally, Worrisome Words, Omicron Overhang, Microsoft CEO's Stock Sales
Satya Nadella's decision to sell almost half his stake in Mr. Softee prompts a closer technical look at what may lie ahead for the tech giant's shares.
Omicron Uncertainty Is Causing Fresh Selling
The challenge for traders is determining how long the Omicron uncertainty will weigh on the markets.
5 Reasons to Bet on Biotech
Small-cap biotech names are seeing dramatic, widespread declines, creating a liquidation sale for investors.
A Light at the End of the Runway
Look for business travel to pick up in a big way in 2022 as the pandemic winds down, which is why American Airlines is a stock to consider.
Jim Cramer: Here's My List of 15 Positives That Must Pan Out
Let's look at how we can go higher and what must go right before the advance has staying power.
The Index Race Ain't Over Yet, So Keep Your Eyes on the RMPIA
The Real Money Post Industrial Average is now up 18.2% -- here's why it could still plow ahead of the Dow and S&P 500.
Jim Cramer: Why Hasn't the Government Pushed for Mass Vaccination?
Incompetence, omissions and even outright lies have categorized this federal attempt to 'stem' the pandemic.
Pfizer's Charts Suggest a Strong Rally Ahead
Here are our latest price targets.
Look No Further Than AbbVie If You Need a Defensive/Dividend Type Name
 AbbVie has been a Sarge fave for a long time. Sarge has been rewarded for trusting this firm's management when they acquired Allergan as a means toward replacing expected reductions in cash flows moving forward as the firm's patents for winder dru...
Jim Cramer: The Drug Cos. Are at Full Strength
We're seeing a group move in pharma right now, so let's sort it out, pill by pill.
Updating Our Bullish Strategy for Regeneron Pharmaceuticals
Here are our new price targets.
Jim Cramer: Let's Saw Through That Home Depot Reaction
We just got hit with a two-by-four, but in your daze, don't confuse this retailer's report with the entire market and economy.
Jim Cramer: The Fortunes Have Been Restored for Regeneron and Abbott
The tables have turned, their stocks have been up, and I think they go higher still.
Abbott Labs Is Poised to Break Out to New Highs
Let's check out the charts of ABT.
Jim Cramer: To Every Market Sector, Turn, Turn, Turn
To the melody of the Byrds' famed song, I want you to know: There's a time to buy the industrials, a time to sell the banks; a time to bid for health cares, a time to dump the techs. ...
For Now, Moderna Is an Options Play For Me
The shares are only trading at 17 times forward earnings, and might not be fully valued just yet.
Regeneron Reaches a Price Target: Let's Take Another Look
Another review of the REGN charts is in order.
Jim Cramer: Monday's Market Is One of the Most Mind-Blowing I've Seen
Buyers make or break companies with their voting or buying or betting. Somedays it's all that matters.
Jim Cramer: I Warned You That Betting Against Science Is a Mug's Game
And I was right, and the cynics were wrong. Here's why that matters more than ever now.
Following Up on Our Regeneron Recommendation
Here's what traders should consider doing now.
ARKK Under Pressure, Peloton, Vaccine Moral Dilemma, Charting the Nasdaq
The fund is at a key spot technically, and there is real fear that if this spot cracks, what looks like a stretch of rough rapids could become a waterfall.
Jim Cramer: Don't Bet Against Comebacks in This Second Chance Market
Just like you have to know how to read a room, you have to know how to read a tape and this tape screams 'I'm not done yet.'
Jim Cramer: We've Got a Boom ... and a Bust
Let's look at this impossible move on the market -- and why health care could be coming off life support.
Here's How I'd Treat Regeneron
It looks like it's time to go long Regeneron, as the charts have improved.
There's No Rush to Purchase Regeneron Stock
The charts are not particularly attractive at this point in time.
Jim Cramer: It's Time for Clear COVID Rules That Make Sense
Outside of the pro sports world, it seems like amateur hour with regard to protocols.
